Trained Innate Immunity Induced by Vaccination with Low-Virulence *Candida* Species Mediates Protection against Several Forms of Fungal Sepsis via Ly6G\(^+\) Gr-1\(^+\) Leukocytes

Elizabeth A. Lilly,\(^a\) Breah E. Bender,\(^a\) Shannon Esher Righi,\(^a\) Paul L. Fidel, Jr.,\(^b\) Mairi C. Noverr\(^a\)

\(^a\)Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA
\(^b\)Center of Excellence in Oral and Craniofacial Biology, Louisiana State University Health Sciences Center School of Dentistry, New Orleans, Louisiana, USA

Paul L. Fidel, Jr., and Mairi C. Noverr contributed equally as senior authors. Order of authors was determined based on project grant funding (PI: Noverr).

**ABSTRACT** We recently discovered a novel form of trained innate immunity (TII) induced by low-virulence *Candida* species (i.e., *Candida dublieniensis*) that protects against lethal fungal/bacterial infection. Mice vaccinated by intraperitoneal (i.p.) inoculation are protected against lethal sepsis following *Candida albicans/Staphylococcus aureus* (*Ca/Sa*) intra-abdominal infection (IAI) or *Ca* bloodstream infection (BSI). The protection against IAI is mediated by long-lived Gr-1\(^+\) leukocytes as putative myeloid-derived suppressor cells (MDSCs) and not by prototypical trained macrophages. This study aimed to determine if a similar TII mechanism (Gr-1\(^+\) cell-mediated suppression of sepsis) is protective against BSI and whether this TII can also be induced following intravenous (i.v.) vaccination. For this, mice were vaccinated with low-virulence *Candida* strains (i.p. or i.v.), followed by lethal challenge (*Ca/Sa* i.p. or *Ca* i.v.) 14 days later, and observed for sepsis (hypothermia, sepsis scoring, and serum cytokines), organ fungal burden, and mortality. Similar parameters were monitored following depletion of macrophages or Gr-1\(^+\) leukocytes during lethal challenge. The results showed that mice vaccinated i.p. or i.v. were protected against lethal *Ca/Sa* IAI or *Ca* BSI. In all cases, protection was mediated by Ly6G\(^+\) Gr-1\(^+\) putative granulocytic MDSCs (G-MDSCs), with no role for macrophages, and correlated with reduced sepsis parameters. Protection also correlated with reduced fungal burden in spleen and brain but not liver or kidney. These results suggest that Ly6G\(^+\) G-MDSC-mediated TII is induced by either the i.p. and i.v. route of inoculation and protects against IAI or BSI forms of systemic candidiasis, with survival correlating with amelioration of sepsis and reduced organ-specific fungal burden.

**IMPORTANCE** Trained innate immunity (TII) is induced following immunization with live attenuated microbes and represents a clinically important strategy to enhance innate defenses. TII was initially demonstrated following intravenous inoculation with low-virulence *Candida albicans*, with protection against a subsequent lethal *C. albicans* intravenous bloodstream infection (BSI) mediated by monocytes with enhanced cytokine responses. We expanded this by describing a novel form of TII induced by intraperitoneal inoculation with low-virulence *Candida* that protects against lethal sepsis induced by polymicrobial intra-abdominal infection (IAI) via Gr-1\(^+\) leukocytes as putative myeloid-derived suppressor cells (MDSCs). In this study, we addressed these two scenarios and confirmed an exclusive role for Ly6G\(^+\) Gr-1\(^+\) leukocytes in mediating TII against either IAI or BSI via either route of inoculation, with protection associated with suppression of sepsis. These studies highlight the previously unrecognized importance of Ly6G\(^+\) MDSCs as central mediators of a novel form of TII termed trained tolerogenic immunity.

**KEYWORDS** trained innate immunity, *Candida* species, myeloid-derived suppressor cells, candidemia, systemic *Candida* infections, *Candida*, immunization, myeloid-derived suppressor cell, sepsis
Lethal sepsis is a common sequela of intra-abdominal infections (IAI) if left untreated or misdiagnosed (1, 2). Our laboratory has been studying fungal/bacterial sepsis using an experimental mouse model of *Candida albicans/Staphylococcus aureus (Ca/SA)* polymicrobial IAI which results in 80 to 90% mortality by 48 to 72 h postinoculation (3–5). Characterization of host responses during Ca/SA polymicrobial IAI demonstrated that mortality is associated with robust inflammation, evidenced by elevated levels of hallmark sepsis-associated proinflammatory mediators (interleukin 6 [IL-6], tumor necrosis factor alpha [TNF-α], IL-1β, and prostaglandin E2 [PGE2]) both locally and systemically, which can be abrogated by treatment with nonsteroidal anti-inflammatory drugs (NSAID) or by targeting PGE2-signaling pathways (4, 5).

Subsequent studies using non-*albicans Candida* (NAC) species in the primary challenge resulted in various levels of mortality. Of these, coinfection with *Candida dubliniensis* (Cd; a close phylogenetic relative of *C. albicans*) and *S. aureus* resulted in minimal mortality (~10 to 20%). Interestingly, surviving mice were highly protected (80 to 90%) against a lethal intraperitoneal (i.p.) challenge with Ca/SA 14 days later. Subsequent studies demonstrated that animals inoculated with a monomicrobial primary i.p. challenge (vaccination) with C. *dubliniensis* were equally highly protected (80 to 90%) against lethal Ca/SA IAI. This protection was long-lived (up to 60 days post-Cd vaccination-challenge), but not mediated by adaptive immunity, with protection maintained in RAG1−/− mice lacking T and B cells. Instead, protection appears to have been mediated by trained innate immunity (TII) that limits infection-associated sepsis. In this model, clodronate-mediated depletion of phagocytic macrophages failed to abrogate protection (6). Rather, a large influx of Gr-1+ (granulocyte receptor 1) leukocytes as early as 4 h post-lethal challenge in primary-challenged mice and the subsequent abrogation of protection following antibody depletion of Gr-1+ cells indicated a novel role for polymorphonuclear neutrophils (PMNs) in mediating protection. With the protective cells functional for at least 60 days postvaccination, and considering the short life span (24 h) of PMNs, these results suggested that the protective Gr-1+ cells were putative, long-lived myeloid-derived suppressor cells (MDSCs), which have been reported for other models of sepsis (7) and for patients with candidiasis (8).

Most recently, we further interrogated this novel form of TII by examining the microbial requirements and spectrum of the protective response. These studies revealed that in addition to Cd, several other low-virulence fungal species (*Saccharomyces cerevisiae, Candida auris, Candida glabrata*, and a *C. albicans* *efg1ΔΔ/cph1ΔΔ* double-null mutant), irrespective of the ability to form true hyphae, conferred similar protection upon Ca/SA lethal challenge (9). Additional characterization revealed the ability of these low-virulence *Candida* species to invade bone marrow by 24 h postvaccination, with a positive correlation between femoral bone marrow fungal infiltration and protection against the lethal IAI challenge. In contrast, while virulent *C. albicans* also infiltrates the bone marrow, there was more evidence of tissue/cellular damage concomitant with reduced protection against lethal challenge. Finally, it was revealed that this protection extended to a lethal intravenous (i.v.) Ca challenge, but with delayed mortality rather than long-term survival. This interesting observation prompted us to design experiments to understand the role of sepsis in the protected mice with delayed mortality, the role of sepsis in the intravenous model in general, and whether a similar Gr-1+ MDSC-mediated TII protection occurs in all the permutations of the systemic model: i.p. vaccination followed by i.v. Ca lethal challenge, as well as i.v. vaccination followed by Ca i.v. or Ca/SA i.p. lethal challenge. There are two main subpopulations of Gr-1+ MDSCs, monocytic Ly6C+ leukocytes (M-MDSCs) and granulocytic Ly6G− leukocytes (G-MDSCs). The relative contribution of each subset varies depending on the experimental model/disease, with adoptive transfer of G-MDSCs reported to ameliorate sepsis (10–12). Therefore, we also evaluated the contribution of G-MDSCs in mediating trained innate immunity in each model of systemic candidiasis.

**RESULTS**

Relative role of leukocyte populations in mediating trained innate immune protection induced by i.p. vaccination followed by i.v. lethal challenge. Based on previous results showing a protective role for Gr-1+ leukocytes induced by
intraperitoneal (i.p.) vaccination with avirulent Candida species against i.p. lethal Ca/Sa challenge, together with protection against i.v. lethal Ca challenge (9), we sought to determine the cell population(s) responsible for the protection against i.v. challenge. We also confirmed that there is no difference in the abilities of our avirulent strains (Cd or C. albicans efg1Δ/Δ cph1Δ/Δ double-null mutant) to induce protection; therefore, both were used throughout, with results combined. For this, mice (n = 10/group) were injected i.p. with liposom-encapsulated clodronate (which results in ~90% depletion of resident peritoneal macrophages) 1 day prior to lethal challenge or 200 μg anti-Gr-1 (Ly6G/C) antibody to deplete Gr-1+ leukocytes 48 h prior to and 2 h after lethal challenge. Antibodies were given every 2 days to the remaining live animals for the duration of the study. Liposomes alone and isotype control antibodies were included as controls. For all studies, mice were monitored for 10 days post-lethal challenge. Animals receiving no primary challenge served as the positive (lethal) controls. Results shown are cumulative of 8 independent experiments. Data were analyzed using the log-rank (Mantel-Cox) test. Actual P values are listed in the table. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05. NS, not significant.

Relative role of leukocyte populations in mediating trained innate immune protection induced by i.v. vaccination followed by i.p. or i.v. lethal challenge.

We next sought to determine if an i.v. route of vaccination could protect against an i.p. or i.v. lethal challenge. For these studies, mice were vaccinated i.v. with a low-virulence Candida strain (Cd or C. albicans efg1Δ/Δ cph1Δ/Δ double-null mutant) followed 14 days later by lethal challenge i.p. (Ca/Sa) or i.v. (Ca alone). Primary i.v. vaccination resulted in significant survival (80 to 90%) against both i.p. and i.v. lethal challenge (Fig. 2A) (P < 0.0001).

Similar cellular depletion experiments were subsequently conducted following the i.v. vaccination. Results show no significant differences in survival between animals treated with liposomal clodronate and liposome vehicle alone prior to i.p. (Ca/Sa) or i.v. (Ca) lethal challenge (Fig. 2B). In contrast, vaccinated mice administered anti-Gr-1 antibodies, but not isotype control antibodies, and challenged i.p. or i.v. showed significantly reduced survival (Fig. 2C).

Gr-1 is a surface receptor and consists of Ly-6G and Ly-6C antigens. Therefore, Gr-1 antibody depletion will affect both Ly6G+ granulocytic cells (neutrophils and G-MDSCs) and Ly6C+ monocytic cells (monocytes and M-MDSCs). Therefore, according to our hypothesis, it was important to confirm that the protection in each model was being mediated...
specifically/predominantly by granulocytic Gr-1+ cells as opposed to monocytes. For this, vaccinated animals were treated with anti-Ly6G antibodies similar to the Gr-1+ cellular depletion for each model just prior to and during the lethal challenge period. As anticipated, in each model, depletion of Ly6G+ cells abrogated the vaccination-mediated protection as evidenced by significantly enhanced mortality compared to that of the animals administered the isotype control antibody (Fig. 3A). Flow cytometry analysis of MDSC populations in the blood and spleens of vaccinated mice confirmed that both Ly6G and Gr-1 antibody treatment specifically depleted G-MDSCs (Fig. 3B and data not shown).

Evidence that protection against i.v. lethal challenge induced by i.p. or i.v. vaccination is associated with reduced sepsis. (i) Hypothermia and sepsis scores. Previous work in our laboratory demonstrated that during polymicrobial intra-abdominal infections (IAI) with Ca and Sa, heightened inflammation and hypothermia, but not
microbial burden, were associated with mortality (3, 4). To investigate this in the lethal i.v. challenge model, core body temperatures of avirulent Candida strain-vaccinated (i.p. or i.v.) mice were compared to those in control lethal challenge mice at day 0 just prior to i.v. lethal challenge and days 2, 4, and 6 post-lethal challenge. In lethal challenge control animals, hypothermia was observed as early as day 2 ($P < 0.0001$) and continued at day 4 ($P < 0.001$) before they all succumbed (Fig. 4). In vaccinated (i.v. or i.p.) mice just prior to lethal challenge, body temperatures were slightly below those of unvaccinated mice ($36.6^\circ C$ versus $37.4^\circ C$, respectively) ($P = 0.012$). Through the observation period temperatures in vaccinated mice varied slightly up and then down by day 4. By day 6, temperatures in the animals given primary i.v. vaccination appeared to return to normal, while temperatures in i.p.-vaccinated mice had a wider range (Fig. 4A). Repeated-measures analysis supported the temperature continuum (vaccinated i.p./i.v., $P = 0.03$; vaccinated i.v./i.v., $P = 0.0012$; unvaccinated, $P = 0.0002$). A portion of the i.p.-vaccinated animals (30 to 40%) were humanely sacrificed before the day 10 endpoint due to behaviors indicative of a neurological condition described previously (9).

As another measure of sepsis, vaccinated (i.p. or i.v.) mice and unvaccinated control mice receiving lethal i.v. challenge only were monitored daily for morbidity (hunched
posture, inactivity, and ruffled fur) and scored using the Mouse Clinical Assessment Score for Sepsis (M-CASS) system (13). Between days 2 and 4 post-lethal challenge, vaccinated animals had significantly lower M-CASS scores than did lethal control mice (\(P < 0.0001\)) that all succumbed by day 4. Thereafter, the M-CASS scores in vaccinated mice continued to be low through the 6-day observation period (Fig. 4B). No differences were observed in sepsis scores between i.p.- and i.v.-vaccinated mice throughout despite the ethical sacrifice of the majority of i.p.-vaccinated mice.

(ii) Systemic cytokine production. We previously demonstrated that during polymicrobial intra-abdominal infections (IAI) with \(Ca\) and \(Sa\), heightened proinflammatory cytokine levels (IL-6, IL-1\(\beta\), and TNF-\(\alpha\)) were closely associated with mortality (4, 5). A similar hyperinflammatory response is also well documented for \(Candida\) bloodstream infections leading to sepsis (14, 15). To determine the effects of i.p. or i.v. vaccination on systemic proinflammatory cytokines, we examined serum IL-6 and TNF-\(\alpha\) at days 2, 4, and 6 post-lethal challenge in vaccinated (i.p. or i.v.) and lethal control animals. Both IL-6 (Fig. 5A) and TNF-\(\alpha\) (Fig. 5B) levels were significantly reduced in i.p.- and i.v.-vaccinated mice.
animals compared to those in lethal control animals at days 2 and 4. Levels of both cyto-
kines continued to be reduced at day 6 in vaccinated mice, when lethal control mice
had expired. No differences in cytokine levels were observed between i.p.- and i.v.-vacci-
nated mice, again despite the forced delayed mortality in i.p.-vaccinated mice.

(iii) Organ fungal burden. Organ fungal burden (brain, spleen, kidney, and liver)
was determined at days 2, 4, and 6 post-lethal challenge. Results in Fig. 6 show that at
days 2 and 4 post-i.v. lethal challenge, significant reductions in CFU were observed in
i.p.- and i.v.-vaccinated animals compared to lethal controls in all organs with the
exception of the liver. Overall, reductions of CFU in vaccinated mice were greatest in
the brain, followed by the spleen and kidney. Notably, the CFU in the kidney were 2
logs higher than in the brain or spleen. After day 4, only vaccinated mice were moni-
tored, as unvaccinated mice had all succumbed. Organ fungal burdens were similar for
i.v.- and i.p.-vaccinated mice throughout the 6 days, with one exception: brain CFU
were significantly reduced at day 2 in i.v.-vaccinated animals compared to those in i.p.-
vaccinated animals ($P = 0.04$) (Fig. 6A), which were ultimately humanely sacrificed
thereafter.

**DISCUSSION**

We previously reported that primary i.p. challenge or vaccination of mice with low-
virulence/attenuated *Candida* species (i.e., *C. dubliniensis*, *C. auris*, *C. glabrata*, and *C.
albicans efg1Δ/D cph1Δ/D*) protects against i.p. or i.v. lethal fungal challenge (sepsis),

**FIG 5** Effect of intraperitoneal or intravenous vaccination with avirulent *Candida* strains on proinflammatory cytokine production following intravenous *C. albicans* infection. Mice ($n = 5$/group) were given primary challenge (i.p. or i.v. vaccination) of the *C. albicans efg1Δ/D cph1Δ/D* mutant 14 days prior to i.v. (*C. albicans*) lethal challenge. Unvaccinated mice (lethal challenge only) were included as controls. Animals were sacrificed for serum collection on days 2, 4, and 6 post-lethal challenge. Serum was analyzed for IL-6 (A) and TNF-α (B) by ELISA. Data are cumulative of 2 independent experiments and were analyzed using the Mann-Whitney U test. **, $P < 0.01$; *, $P < 0.05$. 

September/October 2021 Volume 12 Issue 5 e02548-21 mbio.asm.org
FIG 6 Effect of intraperitoneal or intravenous vaccination with avirulent *Candida* strains on target organ fungal burden following intravenous *C. albicans* infection. Mice (*n* = 5/group) were given primary challenge.

(Continued on next page)
with trained innate protection against lethal Ca/Sa IAI (i.p.) mediated by long-lived Gr-1+ leukocytes (6, 9). These findings prompted us to investigate trained innate protection in several permutations of the models using different routes of vaccination and lethal challenge, the role of sepsis in each, and identification of the cells involved in protection.

Highly significant in the present study is that i.p. or i.v. vaccination with low-virulence Candida species protects against i.p. or i.v. lethal challenge. Mortality in both Ca/Sa IAI (i.p.) and Ca BSI (i.v.) is attributable to sepsis as evidenced by hypothermia observed in these animals as well as significantly high M-CASS scores and increased systemic proinflammatory cytokine production (IL-6 and TNF-α) compared to those in vaccinated mice before they succumb. In all cases, Gr-1+ leukocytes, and specifically/predominantly Ly6G+ leukocytes, are responsible for trained innate protection against lethal sepsis. Considering the short life span (24 h) of polymorphonuclear neutrophils (PMNs), these results continue to support the contention that these long-lived Gr-1+ cells are Ly6G+ G-MDSCs, with similar abrogation of protection observed with Gr-1 or Ly6G antibody-mediated cellular depletion. While this still needs to be confirmed mechanistically, MDSCs are known to be induced in the bone marrow, and we previously reported on the ability of various Candida species to infiltrate bone marrow upon vaccination, with the level of infiltration correlating with protection (9). We also confirmed that both vaccine strains (C. dubliniensis and C. albicans efg1Δ/Δ cph1Δ/Δ) access the bone marrow following either i.p. or i.v. inoculation as early as 24 h but are cleared by day 14, the exception being low-level residual CFU in a small percentage of mice following i.v. inoculation. Therefore, there is a possibility that a sustained presence of avirulent fungal burden in the bone marrow of these mice results in “priming” (continued activation state) as opposed to “training” (cells return to unactivated baseline state) (16). However, the consistency in protection observed in each group argues against this playing a major role. If priming were responsible for protection, animals that cleared the vaccine strain from the bone marrow (80% of mice) would not be protected following lethal challenge. Instead, we observed ~90% protection following i.v. vaccination against either i.p. or i.v. challenge, strongly supporting the contention that innate training is responsible. Other evidence supporting training of Ly6G+ MDSCs (as opposed to continued activation of inflammatory Ly6G+ PMNs) is the reduction in proinflammatory cytokines in all mice concomitant with protection irrespective of route of vaccination.

Consistent with our previous findings, monocytes/macrophages (trained or otherwise) played no role, as demonstrated by the lack of abrogation of protection following liposomal clodronate treatment. A slight reduction in survival was observed in the i.v. vaccination followed by i.p. lethal challenge, but this was not statistically significant compared to results for control mice receiving liposomes only. Nevertheless, we cannot exclude some role for monocytes/macrophages in the i.v. vaccination/i.p. lethal challenge model. In addition, our laboratory previously confirmed no role for T or B cells in the i.p. vaccination/i.p. lethal challenge Ca/Sa IAI model via the use of RAG1−/− mice (6). Results showing the complete abrogation of protection following both Gr-1+ and Ly6G+ cell depletions (which also resulted in the depletion of putative G-MDSCs [Fig. 3B]) in all the other model permutations (i.p. vaccination/i.v. lethal challenge, i.v. vaccination/i.p. lethal challenge, and i.v. vaccination/i.v. lethal challenge) continue to argue against any role for T cells, B cells, macrophages, or monocytes. Hence, our results showing a strong role for trained Ly6G+ Gr-1+ granulocytes in protection continue to build on this novel form of trained innate immunity that inhibits sepsis as the
primary protective mechanism. We have termed this novel TII "trained tolerogenic immunity" (17) as opposed to conventional TII, which involves trained monocytes/macrophages with enhanced immune responsiveness (18, 19). It will be interesting to determine the timing for induction of this trained tolerogenic immunity in the bone marrow postvaccination. Preliminary evidence from our laboratory suggests that it may be 7 days or less.

These unique and novel findings appear to conflict with a seminal TII study by Quintin and colleagues documenting C. albicans functional reprogramming of monocytes in vivo following infection priming (20). These studies employed a similar model of i.v. sublethal primary challenge/i.v. lethal challenge using C. albicans and similarly showed the lack of a role for T and B cells in RAG1−/− mice. To investigate a role for monocytes/macrophages, the authors demonstrated that protection against infection was abrogated in CCR2−/− mice, which are defective in monocyte recruitment/trafficking. For our studies, using a more direct approach of clodronate treatment, which depletes most tissue macrophage populations as well as circulating Ly6C+ monocytes (21), failed to abrogate protection, whereas depletion of Ly6G+ cells significantly abrogated protection. The discrepancy in the findings of these two studies may be partially explained by the less explored role of CCR2 in controlling Gr-1+ neutrophil migration during sepsis or models of acute inflammation (22, 23). Therefore, CCR2 deficiency could potentially also impact Gr-1+ neutrophil and/or MDSC recruitment considering i.v. C. albicans infection results in sepsis. Hence, it is quite possible that the results of both our study and the study by Quintin and colleagues were reflective of protection mediated by trained Gr-1+ MDSC-mediated inhibition of sepsis rather than trained monocyte/macrophage antifungal activity.

The trained innate antisepsis immunity we describe in all the model permutations of lethal sepsis offers the potential for a novel form of vaccination (immune-preventive) against candidemia via induction of Ly6G+ Gr-1+ G-MDSCs. In each of the models (i.p. and i.v. vaccination followed by i.p. or i.v. lethal challenge), significant reductions in hypothermia, sepsis scoring, and serum cytokines correlated with enhanced survival. We also observed significantly reduced fungal burden in target organs, indicating improved antifungal responses that could directly involve MDSCs. Previous studies have demonstrated that Gr-1+ MDSCs have antifungal activity in vitro (8). We hypothesize that the vaccination-induced TII protects against sepsis, thereby allowing time for the innate/adaptive immune response to ultimately eliminate the pathogen.

An interesting observation in the i.p. vaccination route against i.v. lethal challenge is the delayed mortality compared to almost 100% survival in i.v. vaccination against i.v. lethal challenge. In these cases, ethical sacrifice of mice was conducted before the study endpoint due to a neurological condition with behaviors associated with encephalitis (chronic circling). Evidence suggests that sepsis did not prompt this ethical sacrifice, since only slight hypothermia was observed, with low sepsis scores recorded until ethical sacrifice. Instead, the neurological condition appears related to brain fungal burden, which was increased 2 days post-i.v. lethal challenge, followed by considerable variability at 4 days compared to i.v.-vaccinated mice similarly given the i.v. lethal challenge. Notwithstanding of the neurological condition, the animals appeared healthy. This relationship was not shown for fungal burden in the other organs (spleen, kidney, and liver), as organ CFU were similar between the i.p. vaccination/i.v. lethal challenge and i.v. vaccination/i.v. lethal challenge models. Of note as well, mice depleted of Gr-1+ cells succumbed quickly to sepsis, never reaching the ethical sacrifice point. This supports the hypothesis that sepsis was not a factor in the neurological condition and that those mice had indeed been protected against the lethal sepsis.

In terms of fungal burden, kidney and liver burdens were maintained at high levels in both protected and nonprotected control animals. This suggests that kidney and liver burdens are not related to sepsis and do not need to be controlled/reduced for survival. The same is probably true for the spleen and brain despite the reduced CFU correlation with protection. The reduced spleen burden is consistent with the spleen's
role in filtering antigens from the blood and the systemic nature of the lethal infection. There are many reports of high kidney burden in i.v. challenge candidemia models (24–26), although this usually reflects simply a parameter of infection. Our study places into question what role the kidney burden has in mortality versus survival in these challenge models. It is interesting to consider that since Gr-1\(^+\) cells are responsible for protection against i.p. or i.v. lethal challenge, the higher brain and spleen fungal burdens in lethal challenge control mice than in vaccinated mice suggest some level of antifungal activity by Gr-1\(^+\) PMNs in the brains and spleens of mice protected against sepsis.

It is also interesting to consider whether i.p. or i.v. vaccination by low-virulence/attenuated Candida species can protect against sepsis produced by other pathogens/insults. We predict based on the innate training that protection would be observed against several initiators of sepsis. The reverse should be considered as well: can live attenuated childhood vaccines protect against Ca or Ca/Sa sepsis via induction of MDSCs? Current studies in our laboratory are focusing on whether the live attenuated MMR vaccine can induce MDSCs that would protect against i.p. or i.v. lethal challenge with Candida. This general concept is also being investigated with the live attenuated bacillus Calmette-Guérin (BCG) vaccine, which also infiltrates bone marrow and is known to induce trained innate macrophages (27). In these cases, BCG is being evaluated for enhanced nonspecific immunity against unrelated infections.

These concepts are also now being investigated in COVID-19 research. Clinical trials are ongoing using BCG and measles-mumps-rubella (MMR) vaccines to mitigate sequelae of COVID-19. For the BCG vaccine the concept is to induce TII to enhance immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For the MMR vaccine the concept and major endpoint of the clinical trials are to induce trained innate immunity against unrelated infections. The reverse should be considered as well: can live attenuated vaccines protect against COVID-19? This general concept is also being investigated with the live attenuated MMR vaccine can induce MDSCs that protect against i.p. or i.v. lethal challenge with Candida. This general concept is also being investigated with the live attenuated BCG vaccine, which also infiltrates bone marrow and is known to induce trained innate macrophages (27). In these cases, BCG is being evaluated for enhanced nonspecific immunity against unrelated infections.

These concepts are also now being investigated in COVID-19 research. Clinical trials are ongoing using BCG and measles-mumps-rubella (MMR) vaccines to mitigate sequelae of COVID-19. For the BCG vaccine the concept is to induce TII to enhance immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For the MMR vaccine the concept and major endpoint of the clinical trials are to induce trained innate immunity against unrelated infections. The reverse should be considered as well: can live attenuated vaccines protect against COVID-19? This general concept is also being investigated with the live attenuated BCG vaccine, which also infiltrates bone marrow and is known to induce trained innate macrophages (27). In these cases, BCG is being evaluated for enhanced nonspecific immunity against unrelated infections.

**MATERIALS AND METHODS**

**Mice.** Female Swiss Webster mice, 5 to 7 weeks of age, were purchased from Charles River Laboratories. Animals were housed and handled according to institutionally recommended guidelines. All experiments involving animals were approved by the Tulane University School of Medicine Institutional Animal Care and Use Committee.

**Strains and growth conditions.** C. albicans strain DAY185, a prototrophic derivative of SC5314, was a gift from Aaron Mitchell (Carnegie Mellon University, Pittsburgh, PA). The C. albicans efg1ΔΔΔ cph1ΔΔΔ mutant strain (parental strain: SC5314-CAH) was kindly provided by Glen Palmer (University of Tennessee Health Sciences Center, Memphis, TN). The C. dubliniensis wild-type strain (WU284) was kindly provided by Gary Moran (Trinity College, Dublin, Ireland). Frozen stocks were maintained at −80°C and streaked onto yeast peptone dextrose (YPD) agar prior to use. A single colony was transferred to 10 ml YPD broth and shaken at 30°C for 12 to 18 h. The methicillin-resistant Sa strain NRS383 used in i.p. lethal challenge experiments was obtained from the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) data bank. Frozen stocks were maintained at −80°C and streaked onto Trypticase soy agar (TSA) prior to use. A single colony was transferred to 10 ml Trypticase soy broth (TSB) and shaken at 37°C overnight. On the following day, the overnight culture was diluted 1:100 in fresh TSB and shaken at 37°C for 3 h until the culture reached the log phase of growth. Prior to inoculation, organisms were washed 3 times by centrifugation in sterile phosphate-buffered saline (PBS; pH 7.4), counted on a hemocytometer, and diluted in sterile PBS to prepare standardized inocula.

**Vaccination.** Groups (\(n=10\)) of 6-week-old outbred Swiss Webster mice were injected with avirulent Candida strains (C. dubliniensis or C. albicans efg1ΔΔΔ cph1ΔΔΔ mutant strain) intraperitoneally (\(1.75 \times 10^7/mouse\)) in a volume of 200 \(\mu l\) or intravenously (\(1 \times 10^7/mouse\)) in a volume of 100 \(\mu l\) via tail vein injection 14 days prior to lethal challenge. We monitored clearance of vaccine strains from the bone marrow (site of initiation of innate training) following vaccination, with the majority of mice showing undetectable burden by day 14 following i.v. inoculation and only low-level burden in a small percentage of mice following i.v. inoculation (Fig. S3).
**Murine model of fungal-bacterial intra-abdominal infection.** Mice were injected i.p. with a lethal challenge of Sa (8 × 10⁷/mouse) and Sb (1 × 10⁸/mouse) via tail vein injection (100 μl) 14 days after vaccination (i.p. or i.v.). Mice were observed and scored daily for morbidity (hunched posture, inactivity, and ruffled fur) and mortality up to 10 days after rechallenge.

**Murine model of bloodstream infection.** Mice were given a lethal challenge (i.v.) of Ca DAY185 (1 × 10⁷/mouse) via tail vein injection (100 μl) 14 days after vaccination (i.p. or i.v.). Mice were observed and scored daily for morbidity (hunched posture, inactivity, and ruffled fur) and mortality using the Mouse Clinical Assessment Score for Sepsis (M-CASS) (13) for 10 days after lethal i.v. challenge. Control mice received the lethal i.v. challenge only. In some studies, groups of 5 mice were sacrificed on days 2, 4, and 6 post-lethal challenge to assess organ fungal burden and serum cytokine levels. Rectal temperature was measured using a three-quarter-inch rectal probe (ThermoWorks, American Fork, UT) at day 0 and just prior to sacrifice. For this, mice were anesthetized with 3% isoflurane followed by insertion of the probe into the rectum.

**Organ fungal burden.** The brain, spleen, liver, and kidneys were removed from each mouse immediately following sacrifice. Each organ was weighed and homogenized in 1 ml PBS using the PRO 200 tissue homogenizer (PRO Scientific, Oxford, CT). For bone marrow isolation, femurs were isolated from each mouse and each bone was flushed with 5 to 10 ml cold PBS using a 27-gauge needle. Red blood cells (RBCs) were lysed in 1 × RBC lysis buffer (Thermo Fisher), and cells were resuspended in 1 ml sterile PBS. Fungal burden in brain, spleen, liver, and kidneys was enumerated by serial dilution plating of homogenates onto YPD agar containing 20 μg/ml nafcillin and 2 μg/ml vancomycin using the drop plate method (30). Plates were incubated overnight at 37°C. All CFU counts were expressed as the number of CFU per gram tissue. Bone marrow isolated cells were plated neat. Plates were incubated overnight at 37°C. CFU counts were expressed as the number of CFU per gram tissue or CFU per milliliter bone marrow isolated cells.

**Serum cytokine analysis.** Following sacrifice, whole blood was collected by cardiac puncture and allowed to sit overnight at 4°C. Serum was separated by centrifugation at 10,000 g for 2 min, aliquoted, and stored at −80°C until analysis. Concentrations of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) were determined by single-plex enzyme-linked immunosorbent assays (ELISAs; BioLegend, San Diego, CA).

**F4/80⁺ macrophage depletion.** Liposome-encapsulated clodronate and liposome vehicle (1 mg/mouse; Encapsula NanoSciences, Brentwood, TN) were injected i.p. in 200 μl 1 day prior to lethal challenge of animals with Ca/No (i.p.) or Ca alone (i.v.) as previously described (6). Depletion was confirmed by flow cytometry (Fig. S1).

**Gr-1⁺ Ly6G⁺ leukocyte depletion.** Mice were injected i.p. with either 200 μg rat anti-mouse Gr-1 (Ly6G/Ly6C), Ly6G, or rat IgG2A isotype control antibodies (Bio-X-Cell, Lebanon, NH) in 200 μl sterile PBS to systemically deplete PMNs/MDCs 48 h prior to and 2 h after lethal challenge with Ca/No (i.p.) or Ca alone (i.v.). Injections were given every 2 days for the duration of the study. Depletion was confirmed by flow cytometry (Fig. S2).

**Flow cytometry.** To confirm depletion of various cell types, cells were collected from peritoneal lavage fluid, spleen, and/or bone marrow 24 h after the last liposomal clodronate or antibody (anti-Gr-1 or Ly6G) treatment. Following red blood cell lysis, single cell suspensions were incubated with Fc block (BD Biosciences; catalog number 553142) for 10 min on ice and then a combination of the following fluorophores were used to calculate compensation. Fixable viability dye eFluor 506 (eBioscience; catalog number 65-0866-14; 1:100) was included to label dead cells. Following staining, cells were washed twice and fixed with 4% paraformaldehyde for 15 min on ice. Following fixation, cells were washed twice, resuspended in FACS buffer, and stored at 4°C in the dark until analysis. Unstained cells and UltraComp eBeads compensation beads (Invitrogen, Carlsbad, CA) stained with individual fluorophores were used to calculate compensation. Fluorescence-minus-one (FMO) controls were included as gating controls. Cells were collected on a BD LSRII Fortessa flow cytometer (BD Biosciences, San Jose, CA) and the data were analyzed using FlowJo software (FlowJo, LLC, Ashland, OR).

**Statistics.** Survival curves were compared using the log-rank (Mantel-Cox) test. Organ fungal burden, body temperatures, and serum cytokine levels were analyzed using the Mann-Whitney U test. M-CASS sepsis scores were analyzed by Student’s t test. For cellular depletion studies, percentages of positive cells in each group were compared using Student’s t test. Significant differences were defined at a P value of <0.05. All statistical analyses were performed using GraphPad software (GraphPad, San Diego, CA).

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**FIG S1**, TIF file, 1.7 MB.
**FIG S2**, TIF file, 6.3 MB.
**FIG S3**, TIF file, 0.8 MB.

**ACKNOWLEDGMENTS**

This work was supported by NIAID R01AI145096 (M.C.N.). We are grateful for the support, in part, provided by the Louisiana Clinical and Translational Science (LA CaTS)
REFERENCES

1. Blot S, Antonelli M, Arvaniti K, Blot K, Creagh-Brown B, de Lange D, De Waele J, Deschepper M, Dikmen Y, Dimopoulos G, Eckmann C, Francois G, Girardits M, Koulentli D, Leabeau S, Lipman J, Lipovetsky F, Maseda E, Montravers P, Mikstakki A, Paiva JA, Pereyra C, Rello J, Timst JF, Vogelaers D. Abdominal Sepsis Study group on behalf of the Trials Group of the European Society of Intensive Care Medicine. 2019. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: “AbSeS”, a multinational observational cohort study and EDICM Trials Group Project. Intensive Care Med 45: 1703–1717. https://doi.org/10.1007/s00134-019-05819-3.

2. Muresan MG, Balmos IA, Badea I, Santini A. 2018. Abdominal sepsis: an update. J Crit Care Med (Targu Mures) 4:120–125. https://doi.org/10.2478/jccm-2018-0023.

3. Nash EE, Peters BM, Fidel PL, Nover MC. 2016. Morphology-independent virulence of Candida species during polymicrobial intra-abdominal infections with Staphylococcus aureus. Infect Immun 84:90–98. https://doi.org/10.1128/IAI.01059-15.

4. Nash EE, Peters BM, Palmer GE, Fidel PL, Nover MC. 2014. Morphogenesis is not required for Candida albicans-Staphylococcus aureus intra-abdominal infection-mediated dissemination and lethal sepsis. Infect Immun 82: 3426–3433. https://doi.org/10.1128/IAI.01746-14.

5. Peters BM, Nover MC. 2013. Candida albicans-Staphylococcus aureus polymicrobial peritonitis modulates host innate immunity. Infect Immun 81:2178–2189. https://doi.org/10.1128/IAI.00265-13.

6. Lilly EA, Yano J, Esher SK, Hardie E, Fidel PL, Jr, Noverr MC. 2019. Spectrum of trained innate immunity induced by low-virulence Candida species against lethal polymicrobial intra-abdominal infection. Infect Immun 87:2852–2865. https://doi.org/10.1128/IAI.01746-14.

7. Schrijver IT, Theroude C, Roger T. 2019. Myeloid-derived suppressor cells in sepsis. Front Immunol 10:327. https://doi.org/10.3389/fimmu.2019.00327.

8. Schule R, Salih HR, Marodi L, Liese J, Engeholm M, Schultze JL, Stabell Benn C, Xavier RJ, Latz E. 2020. Defining trained immunity and its role in health and disease. Nat Rev Immunol 20:375–388. https://doi.org/10.1038/s41577-020-0285-6.

9. Netea MG, Joosten LA, Latz E, Mills RH, Natoli G, Stunnenberg HG, O'Neill LA, Xavier RJ. 2016. Trained immunity: a program of innate immune memory in health and disease. Science 352:aaf1098. https://doi.org/10.1126/science.aaf1098.

10. Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, Müller M, Blander JM, Tacke F, Trautwein C. 2010. Hepatic acute-phase proteins control suppression of the inflammatory response. J Immunol 185:9143–9155. https://doi.org/10.1016/j.chom.2012.06.006.

11. Derive M, Bouazza Y, Alauzet C, Gibot S. 2017. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Med 45:1717–1728. https://doi.org/10.1007/s00134-019-05819-3.

12. Brudecki L, Ferguson DA, McCall CE, El Gazzar M. 2012. Myeloid-derived suppressor cells in sepsis. Curr Opin Crit Care 18:57–65. https://doi.org/10.1097/MCC.0b013e328355f6f2.

13. Sjostrand A, Bjerke J, Fidebjer K, Stenmark M, Beckebohm L, Vangen A, Sandvold E, Hofvold M. 2014. Alterations of serum cytokine levels and their relation with tolerance: opposing functional programs induced in human monocytes after engagement of various pattern recognition receptors. Clin Vaccine Immunol 21:534–545. https://doi.org/10.1128/CVI.00688-13.

14. Akin H, Akalin H, Budak F, Ener B, Ocako CB, Roth WT, Cheng JJ, Chao S, Jennings J, Sipple D, Yamamoto V, Kateb B, Earnest DL. 2021. MMR vaccination: a potential strategy to reduce severity and mortality of COVID-19 illness. Am J Med 134:153–155. https://doi.org/10.1016/j.amjmed.2020.10.003.

15. Ashford JW, Gold JE, Huenergardt MA, Katz RBA, Strand SE, Bolanos J, Wheeler CJ, Perry G, Smith CJ, Steinman L, Chen MY, Wang JC, Ashford CB, Roth WT, Cheng JJ, Chao S, Jennings J, Sipple D, Yamamoto V, Kateb B, Earnest DL. 2021. MMR vaccination: a potential strategy to reduce severity and mortality of COVID-19 illness. Am J Med 134:153–155. https://doi.org/10.1016/j.amjmed.2020.10.003.

16. Donegan K, Matyac C, Seidler R, Porteous A. 1991. Evaluation of methods for sampling, recovery, and enumeration of bacteria applied to the phylloplane. Appl Environ Microbiol 57:51–56. https://doi.org/10.1128/aem.57.1.51-56.1991.